Kogavant

Ticagrelor, the active ingredient in Kogavant, is a P2Y12 receptor antagonist presented as an oral tablet for oral use. It works by inhibiting platelet aggregation and is used to reduce thrombotic cardiovascular events in patients with acute coronary syndrome and to prevent stent thrombosis following percutaneous coronary intervention.

GNH USA supplies Kogavant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution. The product is sourced from EU‑approved manufacturers and meets stringent regulatory requirements.

Ticagrelor is an antiplatelet agent used in the management of atherosclerotic cardiovascular disease.

- Acute coronary syndrome: Reduces the risk of cardiovascular death, myocardial infarction, and stroke. - Post‑percutaneous coronary intervention (PCI) with stent placement: Prevents stent thrombosis. - Secondary prevention after myocardial infarction: Lowers incidence of recurrent ischemic events.

Ticagrelor may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dyspnea: Shortness of breath, often mild to moderate. - Bleeding: Gum, nose, bruising, or gastrointestinal bleeding. - Headache: Mild to moderate intensity. - Nausea: Occasional upset stomach.

Serious or Rare Side Effects: - Severe bleeding: Intracranial hemorrhage or life‑threatening hemorrhage. - Hypersensitivity reactions: Rash, angioedema, or anaphylaxis. - Elevated liver enzymes: Significant increase in transaminases.

When prescribing ticagrelor, clinicians should consider several precautionary measures to ensure patient safety.

- Assess bleeding risk: Evaluate history of hemorrhage or anticoagulant use. - Monitor hepatic function: Check liver enzymes before and during therapy. - Caution in renal impairment: Dose adjustment may be required in severe cases. - Avoid in patients with active pathological bleeding: Discontinue if bleeding occurs. - Drug interactions: Review concomitant medications that affect CYP3A4. - Store at ambient temperature: Keep below 25 °C in the original packaging, protected from moisture.

Ticagrelor can interact with other medicines, influencing its antiplatelet effect or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): May increase ticagrelor exposure and bleeding risk. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): May reduce efficacy, increasing thrombotic risk.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin, DOACs): Additive bleeding risk; monitor coagulation parameters. - NSAIDs or aspirin: Heightened bleeding tendency; assess necessity. - Statins metabolized by CYP3A4 (e.g., simvastatin): May increase statin levels; consider dose adjustment.